Gene therapy in preeclampsia: the dawn of a new era

References

• Magee LA, Brown MA, Hall DR, et al. The 2021 international society for the study of hypertension in pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2022;27:148–11. doi: 10.1016/j.preghy.2021.09.008
   PubMed Web of Science ®Google Scholar
• Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2(6):323–333. doi: 10.1016/S2214-109X(14)70227-X
   PubMed Web of Science ®Google Scholar
• Thilaganathan B, Kalafat E. Cardiovascular system in preeclampsia and beyond. Hypertension. 2019;73(3):522–531. doi: 10.1161/HYPERTENSIONAHA.118.11191
   PubMed Web of Science ®Google Scholar
• Bokuda K, Ichihara A. Preeclampsia up to date-what’s going on? Hypertens Res. 2023;46(8):1900–1907. doi: 10.1038/s41440-023-01323-w
   PubMed Web of Science ®Google Scholar
• Hung SK, Lee M-S, Lin H-Y, et al. Impact of hypertensive disorders of pregnancy on the risk of stroke stratified by subtypes and follow-up time. Stroke. 2022;53(2):338–344. doi: 10.1161/STROKEAHA.121.034109
   PubMed Web of Science ®Google Scholar
• Chappell LC, Cluver CA, Kingdom J, et al. Pre-eclampsia. Lancet. 2021;398(10297):341–354. doi: 10.1016/S0140-6736(20)32335-7
   PubMed Web of Science ®Google Scholar
• Colella M, Frérot A, Novais ARB, et al. Neonatal and long-term consequences of fetal growth restriction. Curr Pediatr Rev. 2018;14(4):212–218. doi: 10.2174/1573396314666180712114531
   PubMed Web of Science ®Google Scholar
• Dimitriadis E, Rolnik DL, Zhou W, et al. Pre-eclampsia. Nat Rev Dis Primers. 2023;9(1):8. doi: 10.1038/s41572-023-00417-6
   PubMed Web of Science ®Google Scholar
• Chang CW, Wakeland AK, Parast MM. Trophoblast lineage specification, differentiation and their regulation by oxygen tension. J Endocrinol. 2018;236(1):R43–r56. doi: 10.1530/JOE-17-0402
   PubMed Web of Science ®Google Scholar
• James JL, Carter AM, Chamley LW. Human placentation from nidation to 5 weeks of gestation. Part I: What do we know about formative placental development following implantation? Placenta. 2012;33(5):327–334. doi: 10.1016/j.placenta.2012.01.020
   PubMed Web of Science ®Google Scholar
• Staff AC. The two-stage placental model of preeclampsia: An update. J Reprod Immunol. 2019;134-135:1–10. doi: 10.1016/j.jri.2019.07.004
   PubMed Web of Science ®Google Scholar
• Colson A, Sonveaux P, Debiève F, et al. Adaptations of the human placenta to hypoxia: opportunities for interventions in fetal growth restriction. Hum Reprod Update. 2021;27(3):531–569. doi: 10.1093/humupd/dmaa053
   PubMed Web of Science ®Google Scholar
• Redman CWG, Staff AC, Roberts JM. Syncytiotrophoblast stress in preeclampsia: the convergence point for multiple pathways. Am J Obstet Gynecol. 2022;226(2s):S907–s927. doi: 10.1016/j.ajog.2020.09.047
   PubMedGoogle Scholar
• Deer E, Herrock O, Campbell N, et al. The role of immune cells and mediators in preeclampsia. Nat Rev Nephrol. 2023;19(4):257–270. doi: 10.1038/s41581-022-00670-0
   PubMed Web of Science ®Google Scholar
• Tyrmi JS, Kaartokallio T, Lokki AI, et al. Genetic risk factors associated with preeclampsia and hypertensive disorders of pregnancy. JAMA Cardiol. 2023;8(7):674–683. doi: 10.1001/jamacardio.2023.1312
   PubMed Web of Science ®Google Scholar
• Blaese RM, Culver KW, Miller AD, et al. T lymphocyte-directed gene therapy for ADA − SCID: Initial trial results after 4 years. Science. 1995;270(5235):475–480. doi: 10.1126/science.270.5235.475
   PubMed Web of Science ®Google Scholar
• Couzin J, Kaiser J. Gene therapy. As Gelsinger case ends, gene therapy suffers another blow. Science. 2005;307(5712):1028. doi: 10.1126/science.307.5712.1028b
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118(9):3132–3142. doi: 10.1172/JCI35700
   PubMed Web of Science ®Google Scholar
• David Barrett SM, Wendland A, Rose D, et al. Gene, cell, and RNA therapy landscape: Q4 2023 quarterly data report. 2023.
   Google Scholar
• Peek JL, Wilson MH. Cell and gene therapy for kidney disease. Nat Rev Nephrol. 2023;19(7):451–462. doi: 10.1038/s41581-023-00702-3
   PubMed Web of Science ®Google Scholar
• Anguela XM, High KA. Entering the modern era of gene therapy. Annu Rev Med. 2019;70(1):273–288. doi: 10.1146/annurev-med-012017-043332
   PubMed Web of Science ®Google Scholar
• Hu B, Zhong L, Weng Y, et al. Therapeutic siRNA: state of the art. Signal Transduct Target Ther. 2020;5(1):101. doi: 10.1038/s41392-020-0207-x
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wu Z-Y. Gene therapy for monogenic disorders: challenges, strategies, and perspectives. J Genet Genome. 2023.
   Web of Science ®Google Scholar
• Chavez M, Chen X, Finn PB, et al. Advances in CRISPR therapeutics. Nat Rev Nephrol. 2023;19(1):9–22. doi: 10.1038/s41581-022-00636-2
   PubMed Web of Science ®Google Scholar
• Gao J, Zhang W, Ehrhardt A. Expanding the spectrum of adenoviral vectors for cancer therapy. Cancers (Basel). 2020;12(5):12(5. doi: 10.3390/cancers12051139
   Web of Science ®Google Scholar
• Muruve DA. The innate immune response to adenovirus vectors. Hum Gene Ther. 2004;15(12):1157–1166. doi: 10.1089/hum.2004.15.1157
   PubMed Web of Science ®Google Scholar
• Bulcha JT, Wang Y, Ma H, et al. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021;6(1):53. doi: 10.1038/s41392-021-00487-6
   PubMed Web of Science ®Google Scholar
• Arabi F, Mansouri V, Ahmadbeigi N. Gene therapy clinical trials, where do we go? An overview. Biomed Pharmacother. 2022;153:113324. doi: 10.1016/j.biopha.2022.113324
   PubMed Web of Science ®Google Scholar
• Patil S, et al. The development of functional non-viral vectors for gene delivery. Int J Mol Sci. 2019;20(21):20(21. doi: 10.3390/ijms20215491
   Web of Science ®Google Scholar
• Sainz-Ramos M, Gallego I, Villate-Beitia I, et al. How far are non-viral vectors to come of age and reach clinical translation in gene therapy? Int J Mol Sci. 2021;22(14):7545. doi: 10.3390/ijms22147545
   PubMed Web of Science ®Google Scholar
• Corydon IJ, Fabian-Jessing BK, Jakobsen TS, et al. 25 years of maturation: A systematic review of RNAi in the clinic. Mol Ther Nucleic Acids. 2023;33:469–482. doi: 10.1016/j.omtn.2023.07.018
   PubMedGoogle Scholar
• Herzog RW, Popplewell L. Gene Therapy. In: S. Karger, editor. Fast Facts. 2020. doi: 10.1159/isbn.978-3-318-06667-8
   Google Scholar
• Wu X, He X, Liu F, et al. Development and clinical translation of ex vivo gene therapy. Comput Struct Biotechnol J. 2022;20:2986–3003. doi: 10.1016/j.csbj.2022.06.015
   PubMed Web of Science ®Google Scholar
• Parums DV. Editorial: First regulatory approvals for CRISPR-Cas9 therapeutic gene editing for sickle cell disease and transfusion-dependent beta-thalassemia. Med Sci Monit. 2024;30:e944204. doi: 10.12659/MSM.944204
   PubMed Web of Science ®Google Scholar
• Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. 2021;384(3):252–260. doi: 10.1056/NEJMoa2031054
   PubMed Web of Science ®Google Scholar
• Stadtmauer EA, Fraietta JA, Davis MM, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367(6481). doi: 10.1126/science.aba7365
   PubMed Web of Science ®Google Scholar
• Stock SJ, Norman JE. Medicines in pregnancy. F1000Res. 2019;8:8. doi: 10.12688/f1000research.17535.1
   PubMedGoogle Scholar
• Pels A, Onland W, Berger RMF, et al. Neonatal pulmonary hypertension after severe early-onset fetal growth restriction: post hoc reflections on the Dutch STRIDER study. Eur J Pediatr. 2022;181(4):1709–1718. doi: 10.1007/s00431-021-04355-x
   PubMed Web of Science ®Google Scholar
• Pepe GJ, Albrecht ED. Novel technologies for target delivery of therapeutics to the Placenta during pregnancy: a review. Genes (Basel). 2021;12(8):1255. doi: 10.3390/genes12081255
   PubMed Web of Science ®Google Scholar
• Jones H, Crombleholme T, Habli M. Regulation of amino acid transporters by adenoviral-mediated human insulin-like growth factor-1 in a mouse model of placental insufficiency in vivo and the human trophoblast line BeWo in vitro. Placenta. 2014;35(2):132–138. doi: 10.1016/j.placenta.2013.11.012
   PubMed Web of Science ®Google Scholar
• Keswani SG, Balaji S, Katz AB, et al. Intraplacental gene therapy with Ad-IGF-1 corrects naturally occurring rabbit model of intrauterine growth restriction. Hum Gene Ther. 2015;26(3):172–182. doi: 10.1089/hum.2014.065
   PubMed Web of Science ®Google Scholar
• Swanson AM, Rossi CA, Ofir K, et al. Maternal therapy with Ad.VEGF-A 165 increases fetal weight at term in a guinea-pig model of fetal growth restriction. Hum Gene Ther. 2016;27(12):997–1007. doi: 10.1089/hum.2016.046
   PubMed Web of Science ®Google Scholar
• Tang M, Zhang X, Fei W, et al. Advance in placenta drug delivery: concern for placenta-originated disease therapy. Drug Deliv. 2023;30(1):2184315. doi: 10.1080/10717544.2023.2184315
   PubMed Web of Science ®Google Scholar
• Pritchard N, Kaitu’u-Lino T, Harris L, et al. Nanoparticles in pregnancy: the next frontier in reproductive therapeutics. Hum Reprod Update. 2021;27(2):280–304. doi: 10.1093/humupd/dmaa049
   PubMed Web of Science ®Google Scholar
• Cureton N, Korotkova I, Baker B, et al. Selective targeting of a novel vasodilator to the uterine vasculature to treat impaired uteroplacental perfusion in pregnancy. Theranostics. 2017;7(15):3715–3731. doi: 10.7150/thno.19678
   PubMed Web of Science ®Google Scholar
• Zhang B, Tan L, Yu Y, et al. Placenta-specific drug delivery by trophoblast-targeted nanoparticles in mice. Theranostics. 2018;8(10):2765–2781. doi: 10.7150/thno.22904
   PubMed Web of Science ®Google Scholar
• Babischkin JS, Aberdeen GW, Lindner JR, et al. VasculaR endothelial growth factor delivery to placental basal plate promotes uterine artery remodeling in the primate. Endocrinology. 2019;160(6):1492–1505. doi: 10.1210/en.2019-00059
   PubMed Web of Science ®Google Scholar
• Luan S, Xie R, Yang Y, et al. Acid-responsive aggregated gold nanoparticles for radiosensitization and synergistic chemoradiotherapy in the treatment of esophageal cancer. Small. 2022;18(19):e2200115. doi: 10.1002/smll.202200115
   PubMed Web of Science ®Google Scholar
• Zhang B, Liang R, Zheng M, et al. Surface-functionalized nanoparticles as efficient tools in targeted therapy of pregnancy complications. Int J Mol Sci. 2019;20(15):20(15. doi: 10.3390/ijms20153642
   Web of Science ®Google Scholar
• Dahiya UR, Ganguli M. Exocytosis - a putative road-block in nanoparticle and nanocomplex mediated gene delivery. J Control Release. 2019;303:67–76. doi: 10.1016/j.jconrel.2019.04.012
   PubMed Web of Science ®Google Scholar
• Fein KC, Arral ML, Kim JS, et al. Placental drug transport and fetal exposure during pregnancy is determined by drug molecular size, chemistry, and conformation. JControlled Release. 2023;361:29–39. doi: 10.1016/j.jconrel.2023.07.029
   PubMed Web of Science ®Google Scholar
• Yu J, Jia J, Guo X, et al. Modulating circulating sFlt1 in an animal model of preeclampsia using PAMAM nanoparticles for siRNA delivery. Placenta. 2017;58:1–8. doi: 10.1016/j.placenta.2017.07.360
   PubMed Web of Science ®Google Scholar
• Turanov AA, Lo A, Hassler MR, et al. RNAi modulation of placental sFLT1 for the treatment of preeclampsia. Nature Biotechnol. 2018;36(12):1164–1173. doi: 10.1038/nbt.4297
   Web of Science ®Google Scholar
• Li L, Li H, Xue J, et al. Nanoparticle-mediated simultaneous downregulation of placental Nrf2 and sFlt1 improves maternal and fetal outcomes in a preeclampsia mouse model. ACS Biomater Sci Eng. 2020;6(10):5866–5873. doi: 10.1021/acsbiomaterials.0c00826
   PubMed Web of Science ®Google Scholar
• Li L, Yang H, Chen P, et al. Trophoblast-targeted nanomedicine modulates placental sFLT1 for preeclampsia treatment. Front Bioeng Biotechnol. 2020;8:64. doi: 10.3389/fbioe.2020.00064
   PubMed Web of Science ®Google Scholar
• Davis SM, Hariharan VN, Lo A, et al. Chemical optimization of siRNA for safe and efficient silencing of placental sFLT1. Mol Ther Nucleic Acids. 2022;29:135–149. doi: 10.1016/j.omtn.2022.06.009
   PubMedGoogle Scholar
• Swingle KL, Safford HC, Geisler HC, et al. Ionizable lipid nanoparticles for in vivo mRNA delivery to the placenta during pregnancy. J Am Chem Soc. 2023;145(8):4691–4706. doi: 10.1021/jacs.2c12893
   PubMed Web of Science ®Google Scholar
• Haase N, Foster DJ, Cunningham MW, et al. RNA interference therapeutics targeting angiotensinogen ameliorate preeclamptic phenotype in rodent models. J Clin Invest. 2020;130(6):2928–2942. doi: 10.1172/JCI99417
   PubMed Web of Science ®Google Scholar
• Davenport BN, Jones HN, Wilson RL. Placental treatment with insulin-like growth factor 1 via nanoparticle differentially impacts vascular remodeling factors in guinea pig sub-placenta/decidua. Front Physiol. 2022;13:1055234. doi: 10.3389/fphys.2022.1055234
   PubMed Web of Science ®Google Scholar
• Palmer KR, Tong S, Kaitu’u-Lino TJ. Placental-specific sFLT-1: role in pre-eclamptic pathophysiology and its translational possibilities for clinical prediction and diagnosis. Mol Hum Reprod. 2017;23(2):69–78. doi: 10.1093/molehr/gaw077
   PubMed Web of Science ®Google Scholar
• Thadhani R, Hagmann H, Schaarschmidt W, et al. Removal of soluble fms-like tyrosine kinase-1 by dextran sulfate apheresis in preeclampsia. J Am Soc Nephrol. 2016;27(3):903–913. doi: 10.1681/ASN.2015020157
   PubMed Web of Science ®Google Scholar
• Concord M. Comanche biopharma receives US FDA fast track designation for CBP-4888 for the treatment of sFlt-1 mediated pre-term preeclampsia. 2023. Accessed 2024 May 28. https://comanchebiopharma.com/comanche-biopharma-receives-us-fda-fast-track-designation-for-cbp-4888-for-the-treatment-of-sflt-1-mediated-pre-term-preeclampsia/
   Google Scholar
• Sezer SD, Küçük M, Döger FK, et al. VEGF, PIGF and HIF-1α in placentas of early- and late-onset pre-eclamptic patients. Gynecol Endocrinol. 2013;29(8):797–800. doi: 10.3109/09513590.2013.801437
   PubMed Web of Science ®Google Scholar
• Umapathy A, Chamley LW, James JL. Reconciling the distinct roles of angiogenic/anti-angiogenic factors in the placenta and maternal circulation of normal and pathological pregnancies. Angiogenesis. 2020;23(2):105–117. doi: 10.1007/s10456-019-09694-w
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang Y, Ying Ma J, et al. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension. 2007;50(4):686–692. doi: 10.1161/HYPERTENSIONAHA.107.092098
   PubMed Web of Science ®Google Scholar
• Spencer R, Ambler G, Brodszki J, et al. EVERREST prospective study: a 6-year prospective study to define the clinical and biological characteristics of pregnancies affected by severe early onset fetal growth restriction. Bmc Pregnancy Childbirth. 2017;17(1):43. doi: 10.1186/s12884-017-1226-7
   PubMedGoogle Scholar
• Rissanen TT, Markkanen JE, Gruchala M, et al. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res. 2003;92(10):1098–1106. doi: 10.1161/01.RES.0000073584.46059.E3
   PubMed Web of Science ®Google Scholar
• Rossi C, Lees M, Mehta V, et al. Comparison of efficiency and function of vascular endothelial growth factor adenovirus vectors in endothelial cells for gene therapy of placental insufficiency. Hum Gene Ther. 2020;31(21–22):1190–1202. doi: 10.1089/hum.2020.006
   PubMed Web of Science ®Google Scholar
• Wilson RL, Owens K, Sumser EK, et al. Nanoparticle mediated increased insulin-like growth factor 1 expression enhances human placenta syncytium function. Placenta. 2020;93:1–7. doi: 10.1016/j.placenta.2020.02.006
   PubMed Web of Science ®Google Scholar
• King A, Ndifon C, Lui S, et al. Tumor-homing peptides as tools for targeted delivery of payloads to the placenta. Sci Adv. 2016;2(5):e1600349. doi: 10.1126/sciadv.1600349
   PubMed Web of Science ®Google Scholar
• Lv Y, Lu C, Ji X, et al. Roles of microRnas in preeclampsia. J Cell Physiol. 2019;234(2):1052–1061. doi: 10.1002/jcp.27291
   PubMed Web of Science ®Google Scholar
• Frazier S, McBride MW, Mulvana H, et al. From animal models to patients: the role of placental microRnas, miR-210, miR-126, and miR-148a/152 in preeclampsia. Clin Sci (Lond). 2020;134(8):1001–1025. doi: 10.1042/CS20200023
   PubMed Web of Science ®Google Scholar
• Beards F, Jones LE, Charnock J, et al. Placental homing peptide-microRNA inhibitor conjugates for targeted enhancement of intrinsic placental growth signaling. Theranostics. 2017;7(11):2940–2955. doi: 10.7150/thno.18845
   PubMed Web of Science ®Google Scholar
• Iacomino G. miRnas: The road from bench to bedside. Genes (Basel). 2023;14(2):314. doi: 10.3390/genes14020314
   PubMed Web of Science ®Google Scholar
• Wilson RL, Jones HN. Targeting the dysfunctional placenta to improve pregnancy outcomes based on lessons learned in cancer. Clin Ther. 2021;43(2):246–264. doi: 10.1016/j.clinthera.2020.12.007
   PubMed Web of Science ®Google Scholar
• Gathiram P, Moodley J. The role of the renin-angiotensin-aldosterone system in preeclampsia: a review. Curr Hypertens Rep. 2020;22(11):89. doi: 10.1007/s11906-020-01098-2
   PubMed Web of Science ®Google Scholar
• Verdonk K, Visser W, Van Den Meiracker A, et al. The renin–angiotensin–aldosterone system in pre-eclampsia: the delicate balance between good and bad. Clin Sci (Lond). 2014;126(8):537–544. doi: 10.1042/CS20130455
   PubMed Web of Science ®Google Scholar
• Olearczyk J, Gao S, Eybye M, et al. Targeting of hepatic angiotensinogen using chemically modified siRnas results in significant and sustained blood pressure lowering in a rat model of hypertension. Hypertens Res. 2014;37(5):405–412. doi: 10.1038/hr.2013.155
   PubMed Web of Science ®Google Scholar
• Turco MY, Gardner L, Kay RG, et al. Trophoblast organoids as a model for maternal–fetal interactions during human placentation. Nature. 2018;564(7735):263–267. doi: 10.1038/s41586-018-0753-3
   PubMed Web of Science ®Google Scholar
• Roberts RM, Green JA, Schulz LC. The evolution of the placenta. Reproduction. 2016;152(5):R179–89. doi: 10.1530/REP-16-0325
   PubMed Web of Science ®Google Scholar
• Sakowicz A, Bralewska M, Kamola P, et al. Reliability of rodent and rabbit models in preeclampsia research. Int J Mol Sci. 2022;23(22):23(22. doi: 10.3390/ijms232214344
   Web of Science ®Google Scholar
• Carter AM, Pijnenborg R. Evolution of invasive placentation with special reference to non-human primates. Best Pract Res Clin Obstet Gynaecol. 2011;25(3):249–257. doi: 10.1016/j.bpobgyn.2010.10.010
   PubMed Web of Science ®Google Scholar
• Simon-Tillaux N, Lecarpentier E, Tsatsaris V, et al. Sildenafil for the treatment of preeclampsia, an update: should we still be enthusiastic? Nephrol Dial Transplant. 2019;34(11):1819–1826. doi: 10.1093/ndt/gfy328
   PubMed Web of Science ®Google Scholar
• Bradbury A, Markusic D, Muhuri M, et al. Editorial: Immunogenicity and toxicity of AAV gene therapy. Front Immunol. 2023;14:1227231. doi: 10.3389/fimmu.2023.1227231
   PubMed Web of Science ®Google Scholar
• Sood A, Salih S, Roh D, et al. Signalling of DNA damage and cytokines across cell barriers exposed to nanoparticles depends on barrier thickness. Nat Nanotech. 2011;6(12):824–833. doi: 10.1038/nnano.2011.188
   PubMed Web of Science ®Google Scholar
• Hawkins SJ, Crompton LA, Sood A, et al. Nanoparticle-induced neuronal toxicity across placental barriers is mediated by autophagy and dependent on astrocytes. Nat Nanotech. 2018;13(5):427–433. doi: 10.1038/s41565-018-0085-3
   PubMed Web of Science ®Google Scholar
• Li M, Wang H, Tian L, et al. COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduct Target Ther. 2022;7(1):146. doi: 10.1038/s41392-022-00996-y
   PubMed Web of Science ®Google Scholar
• Schneider H, Brownbill P, Albrecht C. Ex vivo dual perfusion of an isolated cotyledon of human placenta: History and future challenges. Placenta. 2021;107:8–12. doi: 10.1016/j.placenta.2021.02.017
   PubMed Web of Science ®Google Scholar
• Valero L, Alhareth K, Gil S, et al. Assessment of dually labelled PEGylated liposomes transplacental passage and placental penetration using a combination of two ex-vivo human models: the dually perfused placenta and the suspended villous explants. Int J Pharm. 2017;532(2):729–737. doi: 10.1016/j.ijpharm.2017.07.076
   PubMedGoogle Scholar